



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Factor V Leiden (FVL), Prothrombin G20210A and MTHFR C677T Mutations among Patients of Budd- Chiari Syndrome

Thesis

*Submitted for Partial Fulfillment of master
Degree in Clinical Pathology*

By

Ahmad Mahmoud Ahmad Mahmoud

M.B., B.Ch. Faculty of Medicine, Ain shams University

Supervised by

Prof. Dr. Afaf Abdel Aziz Abdel Ghaffar

Professor of Clinical Pathology

Faculty of Medicine - Ain Shams University

Prof. Dr. Mohamed Tarif Hamza

Professor of Clinical Pathology

Faculty of Medicine - Ain Shams University

*Faculty of Medicine
Ain Shams University
2021*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبَّحَانَكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound
gratitude to **Prof. Dr. Afaf Abdel Aziz Abdel
Ghaffar**, Professor of Clinical Pathology, Faculty of Medicine -
Ain Shams University for her keen guidance, kind supervision,
valuable advice and continuous encouragement, which made
possible the completion of this work.*

*I am also delighted to express my deepest gratitude and
thanks to **Prof. Dr. Mohamed Tarif Hamza**, Professor
of Clinical Pathology, Faculty of Medicine - Ain Shams
University, for his kind care, continuous supervision, valuable
instructions, constant help and great assistance throughout this
work.*

*I am so grateful also for **My Beloved Wife** for her
existence in my life and her continuous support.*

Ahmad Mahmoud

List of Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables	iii
List of Figures	v
Introduction	1
Aim of the Work.....	4
Review of Literature	
Budd-Chiari Syndrome	5
Genetics of Budd-Chiari Syndrome.....	27
Subjects and Methods.....	42
Results	52
Discussion	67
Summary and Conclusion.....	75
Recommendations	78
References	79
Arabic Summary	—

List of Abbreviations

Abb.	Full term
ACE.....	Angiotensin-converting enzyme
ACL.....	Anti-Cardiolipin
ALT	Alanine aminotransferase
ANA	Antinuclear antibody
aPC	Activated Protein
APTT.....	Activated partial thromboplastin time
ARMS	Amplification refractory mutation system
AST	Aspartate aminotransferase
BCS	Budd Chiari syndrome
COS	Cut-off sample
CT.....	Computed tomography
DNA.....	Deoxyribonucleic acid
DVT	Deep vein thrombosis
EASL.....	European Association for the Study of Liver
FVL	Factor V Leiden
GZ	Gray zone
HBG	Hemoglobin
HCC	Hepatocellular carcinoma
INR.....	International normalized ratio
IVC.....	Inferior vena cava
JAK2	Janus kinase 2
MPDs	Myeloproliferative disorders
MRI	Magnetic resonance imaging
MTHFR.....	Methylene tetrahydrofolate reductase
NC	Negative control
PC.....	Positive control
PCR.....	Polymerase chain reaction
PE	Pulmonary embolism
PGM.....	Phosphoglucomutase
PLT.....	Platelet
PT	Prothrombin time

List of Abbreviations Cont...

Abb.	Full term
PTT.....	Partial thromboplastin time
PV.....	Polycythemia Vera
RBCS	Red blood cells
RFLP	Restriction fragment length polymorphism
rt-PA.....	Recombinant tissue-type plasminogen activator
SNP	Single nucleotide polymorphism
SVT	Splanchnic vein thrombosis
TIPS.....	Transjugular intrahepatic portacaval shunt
VTE.....	Venous thromboembolism
WBC	White blood cell

List of Tables

Table No.	Title	Page No.
Table (1):	Workup in newly diagnosed Budd-Chiari patient.	20
Table (2):	Temperature profile	49
Table (3):	Interpretation of genotyping results using normalized ratios.	50
Table (4):	Distribution of the studied cases according to demographic data, clinical presentation and risk factors.....	53
Table (5):	Distribution of the studied cases according to RBCS, HBG, WBC, PLT, ANA, ACL IgM, ACL IgG, PC DEF, PS DEF, AT III DEF, FVLM, PGM, MTHFR and JAK2 M	55
Table (6):	Comparison between Negative FVLM (no. =12) and FVLM (no. =23) regarding risk factors.	56
Table (7):	Comparison between Negative FVLM (no. =12) and FVLM (no. =23) regarding HBG, RBCS, WBC, PLT, ANA, ACL IgM, ACL IgG, PC DEF, PS DEF and AT III DEF.....	57
Table (8):	Comparison between Negative FVLM (no. =12) and FVLM (no. =23) regarding PGM, MTHFR and JAK2 M	58
Table (9):	Comparison between Negative JAK2 M (no. =29) and JAK2 M (no. =6) regarding Smoking, Thrombosis, Abortion, Hormonal Rx and Pregnancy	59
Table (10):	Comparison between Negative JAK2 M (no. =19) and JAK2 M (no. =6) regarding HBG, RBCS, WBC, PLT, ANA, ACL IgM, ACL IgG, PC DEF, PS DEF and AT III DEF.....	60
Table (11):	Comparison between Negative JAK2 M (no. =19) and JAK2 M (no. =6) regarding PGM, MTHFR and FVLM.....	63
Table (12):	Comparison between Negative MTHFR (no. =18) and MTHFR (no. =17) regarding Smoking, Thrombosis, Abortion, Hormonal Rx and Pregnancy	64

List of Tables Cont...

Table No.	Title	Page No.
Table (13):	Comparison between Negative MTHFR (no. =18) and MTHFR (no. =17) regarding HBG, RBCS, WBC, PLT, ANA, ACL IgM, ACL IgG, PC DEF, PS DEF and AT III DEF.....	65
Table (14):	Comparison between Negative MTHFR (no. =18) and MTHFR (no. =17) regarding PGM, MTHFR and JAK2 M.....	66

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Schematic drawing of the types of Budd-Chiari syndrome according to the location of the obstruction – truncal type (I) with obstruction of the IVC (\pm HV), radicular type (II) with obstruction of HV, venoocclusive type (III) with obstruction of small centrilobular veins	7
Figure (2):	Budd–Chiari syndrome: gross and microscopic appearance of liver and hepatic vein lesions	11
Figure (3):	Site of venous obstruction in veno-occlusive disease, Budd-Chiari syndrome, and congestive hepatopathy	16
Figure (4):	Sonogram showing hepatic vein thrombus, with new vessels forming	21
Figure (5):	A proposed diagnostic and therapeutic work-up for the patient with Budd Chiari syndrome (BCS).....	24
Figure (6):	The homocysteine cycle	37
Figure (7):	HTHFR synthesis and activation.....	38
Figure (8):	Steps of DNA extraction.....	45
Figure (9):	TaqMan probe multiplex assay	46
Figure (10):	Positive heterozygous mutation, dotted curve represent VIC dye (wild gene) while continuous curve represent FAM dye (mutant gene).....	47
Figure (11):	Slan 96P real time PCR System.....	47
Figure (12):	Distribution of the studied cases according to demographic data, clinical presentation and risk factors.....	54

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (13):	The difference between (Negative JAK2 M and JAK2 M) regarding HBG	61
Figure (14):	The difference between (Negative JAK2 M and JAK2 M) regarding RBCS.....	61
Figure (15):	The difference between (Negative JAK2 M and JAK2 M) regarding WBC	62
Figure (16):	The difference between (Negative JAK2 M and JAK2 M) regarding PLT.....	62

INTRODUCTION

BCS is not a primary disease of the liver parenchyma but subsequent liver dysfunction following obstruction of hepatic veins or the suprahepatic Inferior Vena Cava, hepatic venous outflow obstruction results in an elevated sinusoidal pressure and leads to hepatic congestion (*Oblitas et al., 2020*).

Usually, congestion is followed by subsequent centrilobular fibrosis and nodular regenerative hyperplasia that lead to chronic liver dysfunction and cirrhosis; in some instances, however, it results in fulminant hepatic failure requiring emergency liver transplantation (*Robertson and Hayes, 2015*).

There is an interesting but not as yet understood difference in the etiology and epidemiology of this condition in the West and East (*Li et al., 2019*).

The role of the G20210A mutation of the prothrombin gene appears to be negligible in BCS patients (*Valla, 2017; Qi et al., 2016*).

Other recently identified inherited risk factors have not been extensively studied in BCS patients (*Li et al., 2019*).

Thrombophilic abnormalities and clonal disorders of hematopoiesis, such as Philadelphia chromosome negative MPNs both overt and occult, are etiological factors in a significant proportion of BCS cases (*Valla, 2017*).

The prevalence of C677T MTHFR polymorphism appears to be increased in BCS patients worldwide, but a causal association has not been clearly established in European patients (*Qi et al., 2016*).

Many studies from western countries have revealed that primary BCS can be regarded as a multifactorial disease in which several prothrombotic conditions additively predispose patients to develop thrombosis in hepatic veins (*Qi et al., 2016*).

Common prothrombotic conditions associated with BCS include inherited and acquired hypercoagulable states (*Oblitas et al., 2020*).

BCS is a life-threatening group of disorders resulting from hepatic venous outflow obstruction, that may occur at the level of the hepatic venules (hepatic veno-occlusive disease), the large hepatic veins, inferior vena cava (IVC), or the right atrium (congestive hepatopathy) (*Robertson and Hayes, 2015*).

The clinical presentation is highly variable; from being asymptomatic to fulminate, acute, sub-acute, and chronic subtypes depending on duration of the disease, biochemical disturbance, and liver histology (*Robertson and Hayes, 2015*).

FVL (rs6025) is a variant of human factor V which causes an increase in blood clotting (hypercoagulability). Due to this mutation, Protein C, an anticoagulant protein which